P2Y2 receptor regulates VCAM-1 membrane and soluble forms and eosinophil accumulation during lung inflammation

Area of Science:

• Immunology
• Respiratory Medicine
• Molecular Biology

Background:

• Adenosine triphosphate (ATP) is recognized as a key mediator in asthma pathogenesis.
• Purinergic receptors, particularly P2Y(2), play roles in inflammatory processes.

Purpose of the Study:

• To investigate the role of the P2Y(2) purinergic receptor in mediating lung inflammation, specifically eosinophil accumulation.
• To determine the effect of P2Y(2) deficiency on VCAM-1 expression and function in allergic lung inflammation.

Main Methods:

• Evaluated lung inflammation in ovalbumin (OVA)-treated P2Y(2)-deficient and wild-type mice.
• Assessed eosinophil accumulation and VCAM-1 upregulation on lung endothelial cells.
• Performed leukocyte adhesion assays using P2Y(2)-deficient lung endothelial cells.
• Measured soluble VCAM-1 levels in bronchoalveolar lavage fluid (BALF).
• Compared inflammatory cell infiltration (macrophages, neutrophils) in response to lipopolysaccharide (LPS) in P2Y(2)(+/+) and P2Y(2)(-/-) mice.

Main Results:

• OVA-treated P2Y(2)-deficient mice showed defective eosinophil accumulation compared to wild-type mice.
• VCAM-1 upregulation was lower on lung endothelial cells of OVA-treated P2Y(2)(-/-) mice.
• UTP-induced leukocyte adhesion, mediated by endothelial VCAM-1, was abolished in P2Y(2)-deficient cells.
• Soluble VCAM-1 levels were significantly reduced in the BALF of P2Y(2)-deficient mice.
• Macrophage and neutrophil infiltration were comparable in LPS-treated P2Y(2)(+/+) and P2Y(2)(-/-) mice, suggesting a specific role for P2Y(2) in allergic inflammation.

Conclusions:

• The P2Y(2) receptor is a critical regulator of both membrane-bound and soluble VCAM-1 during allergic lung inflammation.
• P2Y(2) signaling is essential for eosinophil accumulation in the lungs.
• These findings highlight P2Y(2) as a potential therapeutic target for managing allergic asthma.